What was the market valuation of the US nonallergic rhinitis market in 2024?

The market valuation was $75.6 Million in 2024. Read More

What is the projected market valuation for the US nonallergic rhinitis market by 2035?

The projected valuation for 2035 is $144.57 Million. Read More

What is the expected CAGR for the US nonallergic rhinitis market during the forecast period 2025 - 2035?

The expected CAGR is 6.07% during the forecast period 2025 - 2035. Read More

Which companies are key players in the US nonallergic rhinitis market?

Key players include GlaxoSmithKline, Sanofi, Boehringer Ingelheim, AstraZeneca, Novartis, Merck & Co., Teva Pharmaceutical Industries, Allergan, and Mylan. Read More

What are the primary diagnostic methods used in the US nonallergic rhinitis market?

Primary diagnostic methods include Physical Examination, Imaging Tests, Nasal Endoscopy, and Allergy Testing, with valuations ranging from $2 Million to $35.57 Million. Read More

What treatment options are available in the US nonallergic rhinitis market?

Treatment options include Nasal sprays, Antihistamines, Corticosteroids, and Decongestants, with valuations between $5 Million and $30 Million. Read More

What are the main end-user segments in the US nonallergic rhinitis market?

Main end-user segments include Hospitals & Clinics, Research Centers, and Others, with valuations from $22.68 Million to $58.25 Million. Read More

How does the market for nasal sprays compare to other treatments in terms of valuation?

Nasal sprays have a valuation range of $15 Million to $30 Million, indicating a competitive position among treatment options. Read More

What is the significance of the projected growth from 2024 to 2035 in the US nonallergic rhinitis market?

The growth from $75.6 Million in 2024 to $144.57 Million in 2035 suggests a robust expansion in the market. Read More

What factors might influence the growth of the US nonallergic rhinitis market in the coming years?

Factors influencing growth may include advancements in treatment options, increased awareness, and the expanding patient population. Read More

US Nonallergic Rhinitis Market

ID: MRFR/Pharma/18443-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Nonallergic Rhinitis Market Research Report By Diagnosis (Physical Examination, Allergy Testing, Imaging Test), By Treatment (Nasal Sprays, Nsaids) and By End User (Hospitals & Clinics, Research Centers) - Growth & Industry Forecast 2025 To 2035

US Nonallergic Rhinitis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.07%

2024 Market Size$ 75.6 Million

2025 Market Size$ 80.19 Million

2035 Market Size$ 144.57 Million

Key Players

GlaxoSmithKline

Sanofi

Boehringer Ingelheim

AstraZeneca

Novartis

Merck & Co.

Trends

Rise of Personalized Treatment Options
Increased Adoption of Telehealth Services
Growing Investment in Research and Development

Opportunities

Focus on Preventive Healthcare
Increasing Healthcare Expenditure
Emergence of Digital Health Solutions

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Diagnosis (USD Million)
  1. 4.1.1 Physical Examination
  2. 4.1.2 Imaging Test
  3. 4.1.3 Nasal Endoscopy
  4. 4.1.4 Computerized Tomography (CT) Scan
  5. 4.1.5 Allergy Testing
  6. 4.1.6 Skin test
  7. 4.1.7 Blood test
  8. 4.1.8 Others
2. 4.2 Chemicals and Materials, BY Treatment (USD Million)
  1. 4.2.1 Nasal sprays
  2. 4.2.2 Antihistamine
  3. 4.2.3 Anti-drip anticholinergic
  4. 4.2.4 Saline
  5. 4.2.5 Decongestants
  6. 4.2.6 Corticosteroid
  7. 4.2.7 NSAIDs
  8. 4.2.8 Others
3. 4.3 Chemicals and Materials, BY End-user (USD Million)
  1. 4.3.1 Hospitals & clinics
  2. 4.3.2 Research centers
  3. 4.3.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Allergan (IE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Mylan (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Nonallergic Rhinitis Market Segmentation

US Nonallergic Rhinitis Market By Diagnosis (USD Million, 2025-2035)

Physical Examination
Imaging Test
Nasal Endoscopy
Computerized Tomography (CT) Scan
Allergy Testing
Skin test
Blood test
Others

US Nonallergic Rhinitis Market By Treatment (USD Million, 2025-2035)

Nasal sprays
Antihistamine
Anti-drip anticholinergic
Saline
Decongestants
Corticosteroid
NSAIDs
Others

US Nonallergic Rhinitis Market By End-user (USD Million, 2025-2035)

Hospitals & clinics
Research centers
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”